The Illinois class action, meanwhile, may clarify the limits of comparative drug advertising in an era when prescription brands function as shorthand for safety, efficacy, and regulatory approval
2 Metabolic dysfunction-associated fatty liver disease and MASLD remain controversial but are not considered superior to each other
Our surgeons possess a deep understanding of the unique anatomical changes caused by massive weight loss via GLP-1 medications
The FDA identifies significant risks including lack of human safety data, potential for adverse immune reactions, and insufficient evidence regarding long-term effects, with the agency authorized to take enforcement action against compounding pharmacies that produce these substances for clinical applications
Mol Aspects Med 28 (5-6), 646-667
La diabetes misma puede ser silenciosa durante los primeros aos, y los sntomas graves como insuficiencia renal o ceguera pueden manifestarse dcadas despus